Pamrevlumab for Idiopathic Pulmonary Fibrosis
Raghu G, Richeldi L, Fernández Pérez E, De Salvo M, Silva R, Song J, Ogura T, Xu Z, Belloli E, Zhang X, Seid L, Poole L, Bowler S, Corte T, Holmes M, Thien F, Wheatley J, Choi S, Chung M, Jeong S, Kim Y, Lee E, Lee H, Park C, Park J, Park J, Chi-Leung Lam D, Chan M, Lee K, Cao J, Chen J, Chen R, Dai H, Fu X, Liang Z, Luo Q, Shi G, Tong Z, Wang L, Yang S, Yu H, Zhang H, Zhang J, Zhao H, Wang W, Meng Y, Peng H, Ramaswamy M, Hamblin M, Fitzgerald J, Gupta N, Dematte J, Veeraraghavan S, O’Brien T, Luckhardt T, Lancaster L, Kokoszynska M, Ettinger N, Kaelin T, Siddiqi A, Collins B, Scholand M, Antin-Ozerkis D, Hyun K, Harden C, Averill F, Mallea J, Bascom R, Seeram V, Hajari Case A, Britt E, Shea B, Criner G, Gotfried M, Mageto Y, El Bayadi S, Reichner C, Mooney J, Hotchkin D, Abrencillo R, Boente R, Lee J, Betensley A, Jeganathan N, Walia R, Albertson T, Rosas I, Puppala D, Abraham L, Enelow R, Bhatt N, Bandyopadhyay D, Elias P, Bergna M, Garcia G, De Stefano G, Wehbe L, Chirino A, Rojas R, Otaola M, Miranda G, Florenzano M, Silva Orellana R, Glasinovich V, Shangina O, Nikishenkov A, Kuzubova N. Pamrevlumab for Idiopathic Pulmonary Fibrosis. JAMA 2024, 332: 380-389. PMID: 38762797, PMCID: PMC11304118, DOI: 10.1001/jama.2024.8693.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisBaseline to weekPulmonary fibrosisAdverse eventsBetween-group differencesPrimary outcomePhase 3 randomized clinical trialSecondary outcomesTreatment-related adverse eventsProgression of idiopathic pulmonary fibrosisPhase 2 trialAssociated with adverse eventsRate of lung function declineSubstantial adverse eventsAbsolute changeStatistically significant between-group differencesPatient-reported symptomsLung function declineSignificant between-group differencesFollow-up encountersPatient-reported outcomesPlacebo groupAntifibrotic treatmentPamrevlumabClinical trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply